Purinergic signaling pathway in severe COVID-19

ARRUVITO, LOURDES; SANANEZ, INÉS; SEERY, VANESA; RUSSO, CONSTANZA; GEFFNER, JORGE

CURRENT OPINION IN PHARMACOLOGY

ELSEVIER SCI LTD

Año: 2023 vol. 70

1471-4892

Substantial efforts have been made to understand the immune response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in order to identify and characterize risk factors, immune mechanisms responsible for the induction of tissue injury and potential therapeutic targets. Purinergic signaling pathway has shown to modulate the inflammatory processes in the course of several infectious diseases, but its role in the coronavirus disease 2019 (COVID-19) has not been clearly defined. Inflammation is usually associated to the release of ATP from different cell types, starting a cascade of events through the activation of a set of different purinergic receptors. This review summarizes the evidence showing the involvement of the purinergic system in the inflammatory condition that characterizes severe COVID-19.